Genmab — Oktober 2022
-
Winkel på Q1 CC: the other program, which I've spoken about at the full year results in February, the Optimus program, which is requiring more dosing iterations, which is certainly going to be asked from Genmab as well as from all other companies in the oncology area and the rationale that perhaps in some combinations, one could use a lower dose of the therapeutic candidates than what is used in monotherapy, Asthika.
-
And that could, of course, slow down a bit the development unless you agree with the regulator to do multiple arm studies. And again, Genmab is now in a position with a better pipeline than we ever had before, a better team that we ever had before in our history and a robust cash position to do actually multiple arm studies also under the Optimus program to actually very quickly titrate and get optimal doses of new therapeutic antibody candidates. So yeah, we are very busy.
-
USA: Beskæftigelsen voksede mere end ventet i september https://www.proinvestor.com/investornyt/887710/usa-beskaeftigelsen-voksede-mere-end-ventet-i-september-ny
-
Renter stiger og aktier falder efter jobtal https://www.proinvestor.com/investornyt/887711/renter-stiger-og-aktier-falder-efter-jobtal-ny
-
MajesTEC-9- A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma https://clinicaltrials.gov/ct2/show/NCT05572515
-
also new- Study of Teclistamab in Combination in Elderly Patients With Multiple Myeloma (IFM 2021-01) -with Dara or Len
https://clinicaltrials.gov/ct2/show/NCT05572229 -
Den omvendte SHS med et "omvendt" hoved, koster en ny ferie. Solgte 20 % af beholdningen i 2740, genkøbt i 2440, solgt i 2770. Jeg kunne jo ikke vente på, at andre skulle kalde en SHS. God weekend til jer alle fra Caribien
-
Der kom en jobrapport forbi hovedet.
-
PS: Tillykke med det flotte sving. God weekend.
-
Fredagens aktier: Kollektiv nedtur på dag med positiv jobrapport https://www.proinvestor.com/investornyt/887813/fredagens-aktier-kollektiv-nedtur-pa-dag-med-positiv-jobrapport
-
Mathai Mammen der pludselig forlod JNJ er kandidat som Biogens nye CEO https://endpts.com/mathai-mammen-emerges-as-top-candidate-for-biogen-ceo-job-stat/
-
Vitus...BSInvest har vist ikke lovet os noget med den formation, han var så venlig at oplyse os om. Den udspillede sig perfekt indtil vi fik arbejdsmarkedstal i US, som sendte alverdens pharma- og biotekaktier ned.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind